​

AbCellera Biologics (ABCL) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABCL Stock Forecast

AbCellera Biologics (ABCL) stock forecast, based on 10 Wall Street analysts, predicts a 12-month average price target of $5.00, with a high of $5.00 and a low of $5.00. This represents a 106.61% increase from the last price of $2.42.

High: $5 Avg: $5 Low: $5 Last Closed Price: $2.42

ABCL Stock Rating

AbCellera Biologics stock's rating consensus is Buy, based on 10 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (90.00%), 1 Hold (10.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 10 0 1 9 Strong Sell Sell Hold Buy Strong Buy

ABCL Price Target Upside V Benchmarks

TypeNameUpside
StockAbCellera Biologics106.61%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$5.67
Last Closing Price$2.42$2.42$2.42
Upside/Downside--134.30%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25261--9
Mar, 25261--9
Feb, 25261--9
Jan, 25261--9
Dec, 24261--9
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Gary NachmanBMO Capital$5.00$2.7482.48%106.61%
Aug 23, 2024Scott SchoenhausKeyBanc$5.00$2.6092.31%106.61%
May 08, 2024Scott SchoenhausKeyBanc$7.00$3.8482.29%189.26%
Jan 06, 2023Leerink Partners$18.00$9.6386.92%643.80%
Dec 15, 2022Andrea TanGoldman Sachs$30.00$10.13196.15%1139.67%
Nov 16, 2022Truist Financial$29.00$14.49100.14%1098.35%
Aug 10, 2022Credit Suisse$34.00$11.85186.92%1304.96%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Nov 05, 2024BMO CapitalOutperformOutperformhold
Aug 23, 2024KeyBancOverweightOverweighthold
Aug 20, 2024BenchmarkBuyHolddowngrade
Jun 28, 2024Cowen & Co.BuyBuyhold
May 08, 2024KeyBancOverweightOverweighthold
Aug 31, 2023BenchmarkBuyBuyhold
Jan 06, 2023SVB LeerinkOutperformOutperformhold
Dec 15, 2022Goldman SachsBuyinitialise
Nov 16, 2022Credit SuisseOutperformNeutralinitialise
Aug 10, 2022Credit SuisseOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.44$0.56$0.56$-0.51$-0.55----
Avg Forecast$0.60$0.52$0.67$-0.46$-0.59$-0.57$-0.49$-0.22$-0.08
High Forecast$1.02$0.90$1.44$-0.41$-0.54$-0.42$-0.29$-0.21$-0.03
Low Forecast$0.33$0.29$0.31$-0.52$-0.61$-0.71$-0.69$-0.23$-0.20
Surprise %-26.67%7.69%-16.42%10.87%-6.78%----

Revenue Forecast

$0 $200M $400M $600M $800M $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$233.16M$375.20M$485.42M$38.02M$28.83M----
Avg Forecast$212.90M$354.36M$519.16M$38.13M$31.58M$43.34M$64.22M$106.56M$145.17M
High Forecast$329.06M$547.69M$982.07M$44.20M$36.12M$89.68M$137.45M$228.07M$310.70M
Low Forecast$140.44M$233.75M$305.35M$35.50M$28.75M$22.51M$30.84M$51.17M$69.71M
Surprise %9.51%5.88%-6.50%-0.27%-8.70%----

Net Income Forecast

$-250M $-110M $30M $170M $310M $450M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$118.92M$153.46M$158.52M$-146.40M$-162.86M----
Avg Forecast$172.92M$151.47M$193.13M$-146.40M$-165.46M$-162.95M$-141.84M$-63.62M$-23.13M
High Forecast$295.56M$258.90M$416.99M$-119.11M$-155.39M$-120.19M$-85.11M$-61.32M$-7.50M
Low Forecast$96.41M$84.45M$89.73M$-149.57M$-175.54M$-205.70M$-198.58M$-65.92M$-57.43M
Surprise %-31.23%1.31%-17.92%--1.58%----

ABCL Forecast FAQ

Is AbCellera Biologics stock a buy?

AbCellera Biologics stock has a consensus rating of Buy, based on 10 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that AbCellera Biologics is a favorable investment for most analysts.

What is AbCellera Biologics's price target?

AbCellera Biologics's price target, set by 10 Wall Street analysts, averages $5 over the next 12 months. The price target range spans from $5 at the low end to $5 at the high end, suggesting a potential 106.61% change from the previous closing price of $2.42.

How does AbCellera Biologics stock forecast compare to its benchmarks?

AbCellera Biologics's stock forecast shows a 106.61% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for AbCellera Biologics over the past three months?

  • April 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is AbCellera Biologics’s EPS forecast?

AbCellera Biologics's average annual EPS forecast for its fiscal year ending in December 2025 is $-0.57, marking a 3.64% increase from the reported $-0.55 in 2024. Estimates for the following years are $-0.49 in 2026, $-0.22 in 2027, and $-0.08 in 2028.

What is AbCellera Biologics’s revenue forecast?

AbCellera Biologics's average annual revenue forecast for its fiscal year ending in December 2025 is $43.34M, reflecting a 50.32% increase from the reported $28.83M in 2024. The forecast for 2026 is $64.22M, followed by $106.56M for 2027, and $145.17M for 2028.

What is AbCellera Biologics’s net income forecast?

AbCellera Biologics's net income forecast for the fiscal year ending in December 2025 stands at $-163M, representing an 0.05% increase from the reported $-163M in 2024. Projections indicate $-142M in 2026, $-63.617M in 2027, and $-23.133M in 2028.